Kezar Life Sciences Overview

  • Founded
  • 2015

Founded
  • Status
  • Public

  • Employees
  • 56

Employees
  • Stock Symbol
  • KZR

Stock Symbol
  • Share Price
  • $7.31

  • (As of Thursday Closing)

Kezar Life Sciences General Information

Description

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 4000 Shoreline Court
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Kezar Life Sciences Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kezar Life Sciences Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.31 $6.90 $4.30 - $18.55 $501M 68.5M 661K -$1.01

Kezar Life Sciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 295,394 773,406 97,265 (1,918)
Revenue 0 0 0 0
EBITDA (63,538) (53,149) (41,406) (36,041)
Net Income (64,270) (54,630) (41,742) (35,087)
Total Assets 304,770 217,933 151,842 89,513
Total Debt 13,316 14,044 5,464 6,364
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kezar Life Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kezar Life Sciences‘s full profile, request access.

Request a free trial

Kezar Life Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Kezar Life Sciences‘s full profile, request access.

Request a free trial

Kezar Life Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel sma
Drug Discovery
South San Francisco, CA
56 As of 2021
00000
000000000 00000

0000 0

ua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut a
0000000000000
Boston, MA
000 As of 0000
00000
0000 0000-00-00
000000&0 00000

000000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
0000 000000000
Heidelberg, Germany
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kezar Life Sciences Competitors (61)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AVEO Oncology Formerly VC-backed Boston, MA 000 00000 000000&0 00000
0000000 Formerly VC-backed Heidelberg, Germany 000 00000 000000000 00000
0000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 61 competitors. Get the full list »

Kezar Life Sciences Patents

Kezar Life Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020228307-A1 Thiazole derivatives as protein secretion inhibitors Pending 28-Feb-2019 0000000000
CA-3131930-A1 Thiazole derivatives as protein secretion inhibitors Pending 28-Feb-2019 0000000000
EP-3930849-A1 Thiazole derivatives as protein secretion inhibitors Pending 28-Feb-2019 0000000000
JP-2022522014-A Thiazole derivative as a protein secretion inhibitor Pending 28-Feb-2019 0000000000
US-20220153732-A1 Protein secretion inhibitors Pending 28-Feb-2019 C07D417/14
To view Kezar Life Sciences’s complete patent history, request access »

Kezar Life Sciences Executive Team (9)

Name Title Board Seat Contact Info
John Fowler Chief Executive Officer & Board Member
Marc Belsky Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Christopher Kirk Ph.D Chief Scientific Officer & Board Member
Nick Mordwinkin Chief Business Officer
Michael Wolfe Vice President, Finance and Business Operations
You’re viewing 5 of 9 executive team members. Get the full list »

Kezar Life Sciences Board Members (11)

Name Representing Role Since
Christopher Kirk Ph.D Kezar Life Sciences Chief Scientific Officer & Board Member 000 0000
Elizabeth Garner Self Board Member 000 0000
Franklin Berger Self Board Member 000 0000
Graham Cooper Self Chairman & Board Member 000 0000
John Fowler Kezar Life Sciences Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Kezar Life Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kezar Life Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kezar Life Sciences‘s full profile, request access.

Request a free trial

Kezar Life Sciences ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

23.99 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 465

Rank

00.00

Percentile

To view Kezar Life Sciences’s complete esg history, request access »